Flaviviruses consist of significant human pathogens responsible for hundreds of millions of
infections each year. Their antigenic relationships generate immune responses that are …

The recently emerged Zika virus (ZIKV) spread to the Americas, causing a spectrum of
congenital diseases including microcephaly in newborn and Guillain-Barré syndrome (GBS) …

Massive viral outbreaks draw attention to viruses that have not been thoroughly studied or
understood. In recent decades, microfluidic chips, known as “lab-on-a-chip”, appears as a …

Hepatitis C virus (HCV) infection affects approximately 58 million people and causes~
300,000 deaths yearly. The only target for HCV neutralizing antibodies is the highly …

More than 390 million human dengue virus (DENV) infections occur each year, worldwide.
Dengvaxia, a live-virus tetravalent vaccine from Sanofi Pasteur, was recently approved for …

The unprecedented 2015–2016 Zika outbreak in the Americas sparked global concern and
drove the rapid deployment of vaccine and therapeutic countermeasures against this re …

Antibody-dependent enhancement (ADE) is a potential concern for the development of Zika
virus (ZIKV) vaccines. Cross-reactive but poorly neutralizing antibodies, usually targeting …

Zika virus (ZIKV) infection and its associated congenital and other neurological disorders,
particularly microcephaly and other fetal developmental abnormalities, constitute a World …

Natural infection of SARS-CoV-2 in humans leads to the development of a strong
neutralizing antibody response, however the immunodominant targets of the polyclonal …

An emergent positive-stranded RNA virus, transmitted by mosquitoes with its first case of
vertical transmission confirmed in 2015 in Brazil. The Zika virus (ZIKV) fever has received …